BACKGROUND AND OBJECTIVES: Blacks are over-represented among dialysis patients, but they have better survival rates than whites. It is unclear if the over-representation of blacks on dialysis is due to faster loss of kidney function or greater survival (or both) in predialysis stages of chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: We compared predialysis mortality, incidence of end stage renal disease (ESRD), and slopes of estimated GFR (eGFR) in 298 black versus 945 white male patients with moderate and advanced nondialysis-dependent CKD (NDD-CKD) from a single medical center. Mortality and ESRD incidence were compared in parametric survival models, and slopes of eGFR were assessed in mixed-effects models. RESULTS: Blacks had lower crude mortality and higher crude ESRD incidence. The lower mortality in blacks was explained by differences in case mix, especially a lower prevalence of cardiovascular disease, and the higher incidence of ESRD was explained by differences in case mix and baseline kidney function. The slopes of eGFR were similar in blacks and whites. CONCLUSIONS: Lower mortality in black versus white patients is also observed in NDD-CKD and can be accounted for by differences in clinical characteristics. Higher mortality of black patients in earlier stages of CKD may result in the selection of a subgroup with fewer comorbidities and better survival in later stages of CKD. The higher crude ESRD rate in blacks appears to result from lower mortality in late stages of CKD, not faster progression of CKD.
BACKGROUND AND OBJECTIVES: Blacks are over-represented among dialysis patients, but they have better survival rates than whites. It is unclear if the over-representation of blacks on dialysis is due to faster loss of kidney function or greater survival (or both) in predialysis stages of chronic kidney disease (CKD). DESIGN, SETTING, PARTICIPANTS & MEASUREMENTS: We compared predialysis mortality, incidence of end stage renal disease (ESRD), and slopes of estimated GFR (eGFR) in 298 black versus 945 white male patients with moderate and advanced nondialysis-dependent CKD (NDD-CKD) from a single medical center. Mortality and ESRD incidence were compared in parametric survival models, and slopes of eGFR were assessed in mixed-effects models. RESULTS: Blacks had lower crude mortality and higher crude ESRD incidence. The lower mortality in blacks was explained by differences in case mix, especially a lower prevalence of cardiovascular disease, and the higher incidence of ESRD was explained by differences in case mix and baseline kidney function. The slopes of eGFR were similar in blacks and whites. CONCLUSIONS: Lower mortality in black versus white patients is also observed in NDD-CKD and can be accounted for by differences in clinical characteristics. Higher mortality of black patients in earlier stages of CKD may result in the selection of a subgroup with fewer comorbidities and better survival in later stages of CKD. The higher crude ESRD rate in blacks appears to result from lower mortality in late stages of CKD, not faster progression of CKD.
Authors: Michelle E Tarver-Carr; Neil R Powe; Mark S Eberhardt; Thomas A LaVeist; Raynard S Kington; Josef Coresh; Frederick L Brancati Journal: J Am Soc Nephrol Date: 2002-09 Impact factor: 10.121
Authors: Daniel E Weiner; Hocine Tighiouart; Manish G Amin; Paul C Stark; Bonnie MacLeod; John L Griffith; Deeb N Salem; Andrew S Levey; Mark J Sarnak Journal: J Am Soc Nephrol Date: 2004-05 Impact factor: 10.121
Authors: J Lewis; L Agodoa; D Cheek; T Greene; J Middleton; D O'Connor; A Ojo; R Phillips; M Sika; J Wright Journal: Am J Kidney Dis Date: 2001-10 Impact factor: 8.860
Authors: R S Levine; J E Foster; R E Fullilove; M T Fullilove; N C Briggs; P C Hull; B A Husaini; C H Hennekens Journal: Public Health Rep Date: 2001 Sep-Oct Impact factor: 2.792
Authors: Nazanin Noori; Csaba P Kovesdy; Ramanath Dukkipati; Usama Feroze; Miklos Z Molnar; Rachelle Bross; Allen R Nissenson; Joel D Kopple; Keith C Norris; Kamyar Kalantar-Zadeh Journal: Am J Nephrol Date: 2011-02-04 Impact factor: 3.754
Authors: Faraz S Ahmad; Xuan Cai; Katherine Kunkel; Ana C Ricardo; James P Lash; Dominic S Raj; Jiang He; Amanda H Anderson; Matthew J Budoff; Julie A Wright Nunes; Jason Roy; Jackson T Wright; Alan S Go; Martin G St John Sutton; John W Kusek; Tamara Isakova; Myles Wolf; Martin G Keane Journal: Am J Hypertens Date: 2017-08-01 Impact factor: 2.689
Authors: Jenna M Norton; Marva M Moxey-Mims; Paul W Eggers; Andrew S Narva; Robert A Star; Paul L Kimmel; Griffin P Rodgers Journal: J Am Soc Nephrol Date: 2016-05-13 Impact factor: 10.121
Authors: Miklos Z Molnar; Robert M Langer; Adam Remport; Maria E Czira; Katalin Rajczy; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Marta Novak; Istvan Mucsi; Laszlo Rosivall Journal: Int Urol Nephrol Date: 2011-11-25 Impact factor: 2.370
Authors: Stephen F Derose; Mark P Rutkowski; Peter W Crooks; Jiaxiao M Shi; Jean Q Wang; Kamyar Kalantar-Zadeh; Csaba P Kovesdy; Nathan W Levin; Steven J Jacobsen Journal: Am J Kidney Dis Date: 2013-03-15 Impact factor: 8.860
Authors: James P Lash; Ana C Ricardo; Jason Roy; Rajat Deo; Michael Fischer; John Flack; Jiang He; Martin Keane; Claudia Lora; Akinlolu Ojo; Mahboob Rahman; Susan Steigerwalt; Kaixiang Tao; Myles Wolf; Jackson T Wright; Alan S Go Journal: Am J Kidney Dis Date: 2016-05-19 Impact factor: 8.860
Authors: Jasmin Divers; Lynne E Wagenknecht; Donald W Bowden; J Jeffrey Carr; R Caresse Hightower; Jianzhao Xu; Carl D Langefeld; Barry I Freedman Journal: Diabetes Care Date: 2009-10-13 Impact factor: 19.112